INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. on November 14, 2018, reporting events occurring on November 12 and 13, 2018. The Company, a developer of reproductive technology, entered into a significant commercial partnership to expand the distribution of its proprietary intravaginal culture device, INVOcell.
Key Financial Metrics and Agreement Terms
The filing details a Distribution Agreement with Ferring International Center S.A. ("Ferring") rather than standard periodic financial results. Key financial terms include:
- Initial Payment: Ferring is obligated to pay $5,000,000 upon satisfaction of closing conditions.
- Contingent Payment: A second payment of $3,000,000 is due if the Company obtains a five-day label enhancement from the FDA for the incubation period at least three years prior to license expiration.
- Supply Revenue: Ferring will pay a specified supply price for each Licensed Product purchased under a separate Supply Agreement.
- Liquidity Impact: The filing does not provide current cash flow, debt, or liquidity metrics; it focuses on future cash inflows contingent on closing and regulatory milestones.
Material Changes and Strategic Shifts
The primary material change is the entry into an exclusive licensing arrangement for the United States market:
- Exclusive License: Ferring receives exclusive rights to market, promote, distribute, and sell INVOcell in the U.S. for reproductive technology uses.
- Commercialization Responsibility: Ferring assumes all costs for commercialization activities in the U.S.
- Company Retention: INVO Bioscience retains rights to establish up to five clinics in the U.S. and retains all commercialization rights outside the United States.
- Closing Conditions: The agreement requires consent from current manufacturers to allow Ferring to assume direct purchase relationships in the event of a material supply default by INVO Bioscience.
Outlook, Risks, and Contingencies
Management commentary is limited to the terms of the agreement. Key outlook factors and risks include:
- Closing Timeline: Closing is not expected prior to January 14, 2019, without mutual consent. If closing does not occur within 75 days, either party may terminate.
- Regulatory Risk: The $3,000,000 contingent payment depends on FDA approval for a label enhancement.
- Performance Risk: The agreement may be terminated by the Company at the end of the initial term (December 31, 2025) if Ferring fails to generate specified minimum revenues during the final two years.
- Termination Rights: Ferring retains the right to terminate the agreement for convenience.
Investor Verification Checklist
- Verify the satisfaction of closing conditions, specifically the agreement from current manufacturers regarding supply defaults.
- Monitor the timeline for the closing of the Distribution Agreement to ensure it occurs within the 75-day window.
- Track FDA regulatory progress regarding the five-day label enhancement for the contingent $3,000,000 payment.
- Review the full text of the Distribution Agreement and Supply Agreement when filed in the Form 10-K for specific supply pricing and revenue thresholds.